Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ivonescimab with doxorubicin and ifosfamide as first-line therapy for unresectable recurrent or metastatic soft tissue sarcoma
ChiCTR2500101628Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab, doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ivonescimabdoxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2500101628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101628.